If doctors could see their patients with chronic conditions every day, what would they check?
That, essentially, is the question that the collaborators at Wellframe asked when they developed Heart Coach, a smartphone-based application that gives patients undergoing cardiac rehabilitation a series of daily tasks, such as taking medication, walking, doing an eye check, watching an instructional video, or completing a survey.1
Trishan Panch, MD, MPH, co-founder and chief medical officer for Wellframe, described the technology, which won the challenge set forth by Merck and the Heritage Provider Network (HPN): to develop a system for managing population health. The application will prove quite valuable as healthcare moves away from the traditional fee-for-service model.
Wellframe’s mission is to use technology to help patients recover from acute health crises and avoid repeat episodes.2 Of course, heart attacks and strokes typically do not happen out of the blue—they are often the result of failing to manage a chronic condition, such as diabetes or hypertension. In an interview with Evidence-Based Diabetes Management, Panch described the well-known challenge of managing these conditions: “It requires sustained coordination and action,” between doctor and patient, he said, and it can be really hard for doctors to motivate patients every day.
Technology’s role, as Panch explained, is to provide not only that between-visit monitoring but also the motivation. What Wellframe has found, he said, is that the technology helps, but what really matters is the relationship that develops over time as patients check-in daily. Of course, the check-ins also catch things that go awry and require immediate attention, Panch said.
The model shifts the definition of who is the “provider,” he said. “Patients provide their own health,” he said. People like physicians, nurses, or diabetes educators “provide the raw materials.”
Wellframe recently published results for 26 patients enrolled in cardiac rehabilitation who used the Heart Coach for 30 days. Researchers found that patients engaged with the application for 90% of the days during the study period, with “uniformly favorable impact on compliance and adherence.”1 The authors reported that 83% of patients reported a positive or very positive experience with the Heart Coach; providers reported improved communication and patient participation, and that the application “enhanced their provision of therapy.”1
Panch noted that patients aged 65 years and older responded very well to the smartphone application, and those aged 75 years and older felt especially strong about its usefulness. Panch said this reflects the patients’ knowledge that “they need to be on top of this on a day-to-day basis.”References
1. Forman DE, LaFond K, Panch T, Allsup K, Manning K, Sattelmair, J. Utility and efficacy of a smartphone application to enhance the learning and behavior goals of traditional cardiac rehabilitation: a feasibility study [published online May 23, 2014]. J Cardiopulm Rehabil Prev. doi:10.1097/HCR.0000000000000058.
2. Wellframe website. http://wellfra.me/. Accessed July 7, 2014.
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen